Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Annual EBITDA margin expands by 170 basis points
Subscribe To Our Newsletter & Stay Updated